The importance of omega-3 fatty acids for behaviour, cognition and mood

References

• Nyden A, Paananen M, Gillberg C. Neuropsychiatric problems among children are significantly underdiag-nosed. Intervention programs result in better and less expensive care. Lakartidningen 2000; 97: 5634–41.
   Google Scholar
• Richardson AJ, Ross MA. Fatty acid metabolism in neurodevelopmental disorder: a new perspective on associations between attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 1–9.
   PubMed Web of Science ®Google Scholar
• Peet M, Glen I, Horrobin DF, eds. Phospholipid spectrum disorder in psychiatry. Carnforth: Marius Press; 1999.
   Google Scholar
• Bennett CN, Horrobin DF. Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 47–59.
   PubMed Web of Science ®Google Scholar
• Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 2002; 56: 365–79.
   PubMed Web of Science ®Google Scholar
• Yehuda S, Rabinovitz S, Mostofsky DI. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neurosci Res 1999; 56: 565–70.
   PubMed Web of Science ®Google Scholar
• Bourre JM, Dumont 0, Piciotti M, et al. Essentiality of omega 3 fatty acids for brain structure and function. World Rev Nutr Diet 1991; 66: 103–17.
   Google Scholar
• Uauy R, Hoffman DR, Peirano P, et al. Essential fatty acids in visual and brain development. Lipids 2001; 36: 885–95.
   PubMed Web of Science ®Google Scholar
• Pawlosky RJ, Hibbeln JR, Novotny JA, Salem N Jr. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J Lipid Res 2001; 42: 1257–65.
   PubMed Web of Science ®Google Scholar
• Burdge GC, Jones AE, Wootton SA. Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men. Br J Nutr 2002; 88: 355–63.
   PubMed Web of Science ®Google Scholar
• Burdge GC, Wootton SA. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and doco-sahexaenoic acids in young women. Br J Nutr 2002; 88 (4): 411–20.
   PubMed Web of Science ®Google Scholar
• Brenner RR. Nutritional and hormonal factors influencing desaturation of essential fatty acids. Prog Lipid Res 1981; 20: 41–7.
   PubMedGoogle Scholar
• Simon JA, Fong J, Bernert JT Jr, Browner WS. Relation of smoking and alcohol consumption to serum fatty acids. Am J Epidemiol 1996; 144: 325–34.
   Google Scholar
• Horrobin DF. Essential fatty acid metabolism and its modification in atopic eczema. Am J Clin Nutr 2000; 71(Suppl 1): 367S-72S.
   Google Scholar
• Horrobin DF. The roles of essential fatty acids in the development of diabetic neuropathy and other complications of diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 1988; 31: 181–97.
   PubMed Web of Science ®Google Scholar
• Colquhoun I, Bunday S. A lack of essential fatty acids as a possible cause of hyperactivity in children. Med Hypotheses 1981; 7: 673–9.
   PubMed Web of Science ®Google Scholar
• Cross-National Collaborative Group. The changing rate of major depression. Cross-national comparisons. JAMA 1992; 268: 3098–105.
   Google Scholar
• Maes M, Smith R, Christophe A, et al. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 1996; 38: 35–46.
   PubMed Web of Science ®Google Scholar
• Horrobin DF. Phospholipid metabolism and depression: the possible roles of phospholipase A2 and coenzyme A-independent transacylase. Hum Psychopharmacol 2001; 16: 45–52.
   PubMed Web of Science ®Google Scholar
• Leonard BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 767–80.
   PubMed Web of Science ®Google Scholar
• Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002; 5: 401–12.
   PubMed Web of Science ®Google Scholar
• Puri BK, Counsell SJ, Hamilton G, et al. Eicosapentaenoic acid in treatmentresistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover. Int J Clin Pract 2001; 55: 560–3.
   PubMed Web of Science ®Google Scholar
• Puri BK, Counsell SJ, Richardson AJ, Horrobin DF. Eicosapentaenoic acid in treatmentresistant depression. Arch Gen Psychiatry 2002; 59: 91–2.
   PubMedGoogle Scholar
• Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159: 477–9.
   PubMed Web of Science ®Google Scholar
• Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59: 913–9.
   PubMed Web of Science ®Google Scholar
• Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407–12.
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 2003; 160: 167–9.
   PubMed Web of Science ®Google Scholar
• Gesch CB, Hammond SM, Hampson SE, et al. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomised, placebo-controlled trial. Br J Psychiatry 2002; 181: 22–8.
   PubMed Web of Science ®Google Scholar
• Puri BK, Richardson AJ. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Arch Gen Psychiatry 1998; 55: 188–9.
   PubMed Web of Science ®Google Scholar
• Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49: 243–51.
   PubMed Web of Science ®Google Scholar
• Peet M, Horrobin DF, E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7–18.
   Google Scholar
• Emsley R, Myburgh C, Oosthuizen P, vanRensburg SJ. Randomized, placebo-controlled study of ethyleicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 1596–8.
   Google Scholar
• Puri BK, Richardson AJ, Horrobin DF, et al. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Int J Clin Pract 2000; 54: 57–63.
   PubMed Web of Science ®Google Scholar
• Richardson AJ, Easton T, Puri BK. Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid. Eur Neuropsychopharmacol 2000; 10: 189–93.
   PubMed Web of Science ®Google Scholar
• Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158: 2071–4.
   PubMed Web of Science ®Google Scholar
• Horrobin DF. Omega-3 fatty acid in schizophrenia. Am J Psychiatry 2003; 160: 188–9.
   PubMed Web of Science ®Google Scholar
• Fenton WS, Dickerson F, Boronow J, et al. Dr Fenton and colleagues reply. Am J Psychiatry 2003; 160: 189.
   Google Scholar
• Vaddadi K. Dyskinesias and their treatment with essential fatty acids: a review. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 89–94.
   Google Scholar
• Nilsson A, Horrobin DF, Rosengren A, et al. Essential fatty acids and abnormal involuntary movements in the general male population: a study of men born in 1933. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 83–7.
   PubMedGoogle Scholar
• Puri BK, Bydder GM, Counsell SJ, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002; 13: 123–6.
   PubMed Web of Science ®Google Scholar
• Richardson AJ, Puri BK. The potential role of fatty acids in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 79–87.
   PubMed Web of Science ®Google Scholar
• Aman MG, Mitchell EA, Turbott SH. The effects of essential fatty acid supplementation by Efamol in hyperactive children. J Abnorm Child Psychol 1987; 15: 75–90.
   PubMed Web of Science ®Google Scholar
• Arnold LE, Kleykamp D, Votolato NA, et al. Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biol Psychiatry 1989; 25: 222–8.
   PubMed Web of Science ®Google Scholar
• Burgess JR. Attention deficit hyperactivity disorder: observational and interventional studies. In: NIH work-shop on omega-3 essential fatty acids and psychiatric disorders, 2–3 September 1998. Bethesda, MD: National Institutes of Health; 1998.
   Google Scholar
• Richardson AJ, Puri BK. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 233–9.
   PubMed Web of Science ®Google Scholar
• Voigt RG, Llorente AM, Jensen CL, et al. A randomized, double-blind, placebo-controlled trial of docosa-hexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 2001; 139: 189–96.
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Biederman J, Wozniak J, et al. Parsing pediatric bipolar disorder from its associated comorbidity with the disruptive behavior disorders. Biol Psychiatry 2001; 49: 1062–70.
   Google Scholar
• Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry 1989; 28: 882–7.
   PubMed Web of Science ®Google Scholar
• DuPaul GJ, Barkley RA, McMurray MB. Response of children with ADHD to methylphenidate: interaction with internalizing symptoms. J Am Acad Child Adolesc Psychiatry 1994; 33: 894–903.
   PubMed Web of Science ®Google Scholar